Biology and treatment of childhood T-lineage acute lymphoblastic leukemia

Blood

Volumn 91, Issue 3, 1998, Pages 735-746

  Uckun, Fatih M ^a   Sensel, Martha G ^b   Sun, Lei ^b   Steinherz, Peter G ^b   Trigg, Michael E ^b   Heerema, Nyla A ^b   Sather, Harland N ^b   Reaman, Gregory H ^b   Gaynon, Paul S ^b  

^a Department of Genetics   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; C 506; CYTARABINE; DAB 486 INTERLEUKIN 2; DAUNORUBICIN; DEOXYGUANOSINE DERIVATIVE; DEXAMETHASONE; DIPHTHERIA TOXIN; DOXORUBICIN; GLUCOCORTICOID RECEPTOR; IFOSFAMIDE; IMMUNOTOXIN; INTERLEUKIN 2; MAFOSFAMIDE; METHOTREXATE; NELARABINE; PREDNISONE; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; GENE MUTATION; HUMAN; HUMAN CELL; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, T-CELL, ACUTE; MUTATION; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 0032005253     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Poplack D: Acute lymphoblastic leukemia, in Pizzo P, Poplack D (eds): Principles and Practice of Pediatric Oncology (ed 2). Philadelphia, PA, Lippincott, 1993, p 431
2. Greaves MF: Differentiation-linked leukemogenesis in lymphocytes. Science 234:697, 1986
3. Smith LJ, Curtis JE, Messner HA, Senn JS, Furthmayr H, McCulloch EA: Lineage infidelity in acute leukemia. Blood 61:1138, 1983
4. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE: Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group study. Blood 72:1891, 1988
5. Borowitz MJ, Dowell BL, Boyett JM, Pullen DJ, Crist WM, Quddus FM, Falletta JM, Metzgar RS: Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 4:170, 1986
6. Uckun F, Reaman G, Steinherz P, Arthur D, Sather H, Trigg M, Tubergen D, Gaynon P: Improved outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A children's cancer group study. Leuk Lymphoma 24:57, 1996
7. Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH: Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: Results and prognostic factors (a Pediatric Oncology Group study). Blood 60:1159, 1982
8. Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 75:166, 1990
9. Dowell BL, Borowitz MJ, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Russell EC, Falletta JM, Metzgar RS: Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group study. Cancer 59:2020, 1987
10. Garand R, Vannier JP, Bene MC, Faure G, Favre M, Bernard A: Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. the Groupe D'Etude Immunologique Des Leucemies. Leukemia 4:739, 1990
11. Clavell LA, Gelber RD, Cohen HJ, Hitchcock Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657, 1986
12. Gaynon P, Steinherz P, Bleyer WA, Ablin A, Albo V, Finkelstein J, Grossman N, Littman P, Novak L, Pyesmany A, Reaman G, Sather H, Hammond D: Intensive therapy for children with acute lymphoblastic leukemia and unfavorable presenting features. Lancet 2:921, 1988
13. Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, Evans RG, Meyers P, Steinherz LJ, Sather H, Hammond D: Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - A new intensive therapy protocol: A report from the Children's Cancer Study Group. J Clin Oncol 4:744, 1986
14. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
15. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R: Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 81:1704, 1996
16. Lin YW, Kubota M, Wakazono Y, Hirota H, Okuda A, Bessho R, Usami I, Kataoka A, Yamanaka C, Akiyama Y, Furusho K: Normal mutation frequencies of somatic cells in patients receiving growth hormone therapy. Mutat Res 362:97, 1996
17. Rapaport R, Oberfield SE, Robison L, Salisbury S, David R, Rao J, Redmond GP: Relationship of growth hormone deficiency and leukemia. J Pediatr 126:759, 1995
18. Linet MS, Hatch EE, Kleinerman RA, Robison LL, Kaune WT, Friedman DR, Severson RK, Haines SM, Hartsock CT, Niwa S, Wacholder S, Tarone RE: Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. N Engl J Med 337:1, 1997
19. Alexander FE: Space-time clustering of childhood acute lymphoblastic leukaemia: Indirect evidence for a transmissible agent. Br J Cancer 65:589, 1992
20. Alexander FE: Viruses, clusters and clustering of childhood leukaemia: A new perspective? Eur J Cancer 29A:1424, 1993
21. Kinlen L: Evidence for an infective cause of childhood leukaemia: Comparison of a Scottish New Town with nuclear reprocessing sites in Britain. Lancet 2:1323, 1988
22. Petridou E, Revinthi K, Alexander FE, Haidas S, Koliouskas D, Kosmidis H, Piperopoulou F, Tzortzatou F, Trichopoulos D: Space-time clustering of childhood leukaemia in Greece: Evidence supporting a viral aetiology. Br J Cancer 73:1278, 1996
23. van Steensel Moll HA, Valkenburg HA, van Zanen GE: Childhood leukemia and parental occupation: A register-based case-control study. Am J Epidemiol 121:216, 1985
24. Wachsman W, Golde D, Chen I: HTLV and human leukemia: Perspectives. Semin Hematol 23:245, 1986
25. Williams D, Ragab A, McDougal J: HTLV-I antibodies in childhood leukemia. JAMA 253:2496, 1985
26. Lin KH, Su IJ, Chen RL, Lin DT, Tien HF, Chen BW, Lin KS: Peripheral T-cell lymphoma in childhood: A report of five cases in Taiwan. Med Pediatr Oncol 23:26, 1994
27. Toledano SR, Lange BJ: Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 45:1675, 1980
28. Aurias A, Dutrillaux B, Buriot D, Lejeune J: High frequencies of inversions and translocations of chromosomes 7 and 14 in ataxia telangiectasia. Mutat Res 69:369, 1980
29. Heppell A, Butterworth SV, Hollis RJ, Kennaugh AA, Beatty DW, Taylor AM: Breakage of the T cell receptor alpha chain locus in non malignant clones from patients with ataxia telangiectasia. Hum Genet 79:360, 1988
30. Russo G, Isobe M, Pegoraro L, Finan J, Nowell PC, Croce CM: Molecular analysis of a t(7;14)(Q35;Q32) chromosome translocation in a T cell leukemia of a patient with ataxia telangiectasia. Cell 53:137, 1988
31. Hollis RJ, Kennaugh AA, Butterworth SV, Taylor AM: Growth of large chromosomally abnormal T cell clones in ataxiatelangiectasia patients is associated with translocation at 14q11: A model for other T cell neoplasia. Hum Genet 76:389, 1987
32. Champlin R, Gale RP: Acute lymphoblastic leukemia: Recent advances in biology and therapy [see comments]. Blood 73:2051, 1989
33. Raimondi SC, Behm FG, Roberson PK, Pui CH, Rivera GK, Murphy SB, Williams DL: Cytogenetics of childhood T-cell leukemia. Blood 72:1560, 1988
34. Kagan J, Finger LR, Letofsky J, Finan J, Nowell PC, Croce CM: Clustering of breakpoints on chromosome 10 in acute T-cell leukemias with the t(10;14) chromosome translocation. Proc Natl Acad Sci USA 86:4161, 1989
35. Zutter M, Hockett RD, Roberts CW, McGuire EA, Bloomstone J, Morton CC, Deaven LL, Crist WM, Carroll AJ, Korsmeyer SJ: The t(10;14)(q24;q11) of T-cell acute lymphoblastic leukemia juxtaposes the delta T-cell receptor with TCL3, a conserved and activated locus at 10q24. Proc Natl Acad Sci USA 87:3161, 1990
36. Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J, Hershfield MS, Haynes BF, Cohen DI, Waldmann TA, Kirsch IR: Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci USA 86:2031, 1989
37. Boehm T, Baer R, Lavenir I, Forster A, Waters JJ, Nacheva E, Rabbitts TH: The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. EMBO J 7:385, 1988
38. Cheng JT, Yang CY, Hernandez J, Embrey J, Baer R: The chromosome translocation (11;14)(p13;q11) associated with T cell acute leukemia. Asymmetric diversification of the translocational junctions. J Exp Med 171:489, 1990
39. Garcia IS, Kaneko Y, Gonzalez Sarmiento R, Campbell K, White L, Boehm T, Rabbitts TH: A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia. Oncogene 6:577, 1991
40. Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS, Vietti TJ: The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 76:1220, 1990
41. Finger LR, Kagan J, Christopher G, Kurtzberg J, Hershfield MS, Nowell PC, Croce CM: Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci USA 86:5039, 1989
42. Chen Q, Yang CY, Tsan JT, Xia Y, Ragab AH, Peiper SC, Carroll A, Baer R: Coding sequences of the tal-1 gene are disrupted by chromosome translocation in human T cell leukemia. J Exp Med 172:1403, 1990
43. Begley CG, Aplan PD, Denning SM, Haynes BF, Waldmann TA, Kirsch IR: The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci USA 86:10128, 1989
44. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR: Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 250:1426, 1990
45. Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR: Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 79:1327, 1992
46. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Carroll AJ, Buchanan GR, Smith RG, Baer R: Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: A Pediatric Oncology Group study. Blood 81:2110, 1993
47. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH: The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 86:47, 1996
48. Pulford K, Lecointe N, Leroy Viard K, Jones M, Mathieu Mahul D, Mason DY: Expression of TAL-1 proteins in human tissues. Blood 85:675, 1995
49. Elwood NJ, Cook WD, Metcalf D, Begley CG: SCL, the gene implicated in human T-cell leukaemia, is oncogenic in a murine T-lymphocyte cell line. Oncogene 8:3093, 1993
50. Dube ID, Raimondi SC, Pi D, Kalousek DK: A new translocation, t(10;14)(q24;q11), in T cell neoplasia. Blood 67:1181, 1986
51. Kennedy MA, Gonzalez Sarmiento R, Kees UR, Lampert F, Dear N, Boehm T, Rabbitts TH: HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad Sci USA 88:8900, 1991
52. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ: Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253:79, 1991
53. Dube ID, Kamel Reid S, Yuan CC, Lu M, Wu X, Corpus G, Raimondi SC, Crist WM, Carroll AJ, Minowada J, Baker JB: A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 78:2996, 1991
54. Dear TN, Sanchez Garcia I, Rabbitts TH: The HOX11 gene encodes a DNA-binding nuclear transcription factor belonging to a distinct family of homeobox genes. Proc Natl Acad Sci USA 90:4431, 1993
55. Yamamoto H, Hatano M, Iitsuka Y, Mahyar NS, Yamamoto M, Tokuhisa T: Two forms of Hox11, a T cell leukemia oncogene, are expressed in fetal spleen but not in primary lymphocytes. Mol Immunol 32:1177, 1995
56. Roberts CW, Shutter JR, Korsmeyer SJ: Hox11 controls the genesis of the spleen. Nature 368:747, 1994
57. Salvati PD, Ranford PR, Ford J, Kees UR: HOX11 expression in pediatric acute lymphoblastic leukemia is associated with T-cell phenotype. Oncogene 11:1333, 1995
58. Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T, Stass S: New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia. Cell 36:101, 1984
59. Ribeiro RC, Raimondi SC, Behm FG, Cherrie J, Crist WM, Pui CH: Clinical and biologic features of childhood T-cell leukemia with the t(11;14). Blood 78:466, 1991
60. Zalcberg IQ, Silva ML, Abdelhay E, Tabak DG, Ornellas MH, Simoes FV, Pucheri W, Ribeiro R, Seuanez HN: Translocation 11;14 in three children with acute lymphoblastic leukemia of T-cell origin. Cancer Genet Cytogenet 84:32, 1995
61. McGuire EA, Hockett RD, Pollock KM, Bartholdi MF, O'Brien SJ, Korsmeyer SJ: The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol 9:2124, 1989
62. Royer Pokora B, Fleischer B, Ragg S, Loos U, Williams D: Molecular cloning of the translocation breakpoint in T-ALL 11;14 (p13;q11): Genomic map of TCR alpha and delta region on chromosome 14q11 and long-range map of region 11p13. Hum Genet 82:264, 1989
63. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH: The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 88:4367, 1991
64. Royer Pokora B, Loos U, Ludwig WD: TTG-2, a new gene encoding a cysteine-rich protein with the lim motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(P13;Q11). Oncogene 6:1887, 1887
65. Wilkinson DA, Neale GA, Mao S, Naeve CW, Goorha RM: Elf-2, a rhombotin-2 binding ets transcription factor: Discovery and potential role in T cell leukemia. Leukemia 11:86, 1997
66. Raimondi SC, Pui CH, Behm FG, Williams DL: 7q32-q36 translocations in childhood T cell leukemia: Cytogenetic evidence for involvement of the T cell receptor beta-chain gene. Blood 69:131, 1987
67. Cleary ML, Mellentin JD, Spies J, Smith SD: Chromosomal translocation involving the beta T cell receptor gene in acute leukemia. J Exp Med 167:682, 1988
68. Mellentin JD, Smith SD, Cleary ML: lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58:77, 1989
69. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649, 1991
70. Burnett RC, David JC, Harden AM, Le Beau MM, Rowley JD, Diaz MO: The Lck gene is involved in the t(1;7)(P34;Q34) in the T-cell acute lymphoblastic leukemia derived cell line, Hsb-2. Gene Chromosom Cancer 3:461, 1991
71. Tycko B, Smith SD, Sklar J: Chromosomal translocations joining lck and tcrb loci in human T cell leukemia. J Exp Med 174:867, 1991
72. Abraham KM, Levin SD, Marth JD, Forbush KA, Perlmutter RM: Thymic tumorigenesis induced by overexpression of P56lck. Proc Natl Acad Sci USA 88:3977, 1991
73. Wildin RS, Garvin AM, Pawar S, Lewis DB, Abraham KM, Forbush KA, Ziegler SF, Allen JM, Perlmutter RM: Developmental regulation of lck gene expression in T lymphocytes. J Exp Med 173:383, 1991
74. Finver SN, Nishikura K, Finger LR, Haluska FG, Finan J, Nowell PC, Croce CM: Sequence analysis of the MYC oncogene involved in the t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates that putative regulatory regions are not altered. Proc Natl Acad Sci USA 85:3052, 1988
75. Erikson J, Williams DL, Finan J, Nowell PC, Croce CM: Locus of the alpha-chain of the T-cell receptor is split by chromosome translocation in T-cell leukemias. Science 229:784, 1985
76. Finger LR, Huebner K, Cannizzaro LA, McLeod K, Nowell PC, Croce CM: Chromosomal translocation in T-cell leukemia line HUT 78 results in a MYC fusion transcript. Proc Natl Acad Sci USA 85:9158, 1988
77. Elledge SJ: Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664, 1996
78. Boise LH, Thompson CB: Hierarchical control of lymphocyte survival. Science 274:67, 1996
79. Stillman B: Cell cycle control of DNA replication. Science 274:1659, 1996
80. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME, Minden MD: Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood 89:2276, 1997
81. Weinberg RA: Tumor Suppressor Genes. Science 254:1138, 1991
82. Hermanson M, Liu Y, Zabarovsky E, Grander D, Gahrton G, Juliusson G, Rasool M, Wu X, Buys C, Yankovsky N, et al: Chromosome 13q14 deletions in lymphoid malignancies (meeting abstract). Proc Am Assoc Cancer Res 36:104, 1995, (abstr 3095)
83. Zhou M, Zaki SR, Ragab AH, Findley HW: Frequent alteration of Rb tumor-suppressor gene in childhood acute lymphoblastic leukemia (meeting abstract). Proc Am Assoc Cancer Res 34:104, 1993 (abstr 616)
84. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
85. Hannon GJ, Beach D: p15ink4b is a potential effector of Tgf-beta-induced cell cycle arrest [see comments]. Nature 371:257, 1994
86. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, CL OK, Matera AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1-and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939, 1994
87. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 15:2682, 1995
88. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57kip2, a structurally distinct member of the p21cip1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650, 1995
89. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9, 1994
90. Rasool O, Heyman M, Brandter LB, Liu Y, Grander D, Soderheall S, Einhorn S: p15ink4b and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood 85:3431, 1995
91. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86:1269, 1995
92. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio Brint AM, Liu Q, Pui CH, Sherr CJ, Beach D, Look AT, Downing JR: Frequent deletion of p16INK4a/MTS1 and p15INK4b/ MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321, 1995
93. Guidai Giroux C, Gerard B, Cave H, Duval M, Rohrlich P, Elion J, Vilmer E, Grandchamp B: Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br J Haematol 92:410, 1996
94. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685, 1995
95. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL: Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57:832, 1997
96. Chilcote RR, Brown E, Rowley JD: Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. N Engl J Med 313:286, 1985
97. Uckun FM, Gajl Peczalska KJ, Provisor AJ, Heerema NA: Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 73:271, 1989
98. Bloomfield CD, Seeker Walker LM, Goldman AI, Van Den Berghe H, de la Chapelle A, Ruutu T, Alimena G, Garson OM, Golomb HM, Rowley JD, Kaneko Y, Whang-Peng J, Prigogina E, Philip P, Sandberg AA, Lawler SD, Mitleman F: Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet 40:171, 1989
99. Sherr CJ: Cancer cell cycles. Science 274:1672, 1996
100. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305, 1995
101. Yeargin J, Cheng J, Haas M: Role of the p53 tumor suppressor gene in the pathogenesis and in the suppression of acute lymphoblastic T-cell leukemia. Leukemia 6 Suppl 3:85s, 1992
102. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145:702, 1994
103. Savitsky K, Bar Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase [see comments]. Science 268:1749, 1995
104. Painter RB, Young BR: Radiosensitivity in ataxia-telangiectasia: A new explanation. Proc Natl Acad Sci USA 77:7315, 1980
105. Xu Y, Baltimore D: Dual roles of ATM in the cellular response to radiation and in cell growth control [see comments]. Genes Dev 10:2401, 1996
106. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D: Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma [see comments]. Genes Dev 10:2411, 1996
107. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw Boris A: Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86:159, 1996
108. Taylor A, Metalfe J, Thick J, Mak Y: Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423, 1996
109. Spector B, Filipovich A, Perry G, Kersey K: Epidemiology of cancer in ataxia telangiectasia, in Bridges B, Harnden D (eds): A Cellular and Molecular Link Between Cancer, Neuropathology, and Immune Deficiency. Chichester, UK, Wiley, 1982, p1
110. Collyn dHooghe M, Galiegue Zouitina S, Szymiczek D, Lantoine D, Quief S, Loucheux Lefebvre MH, Kerckaert JP: Quantitative and qualitative variation of ETS-1 transcripts in hematologic malignancies. Leukemia 7:1777, 1993
111. Georgopoulos K, Moore DD, Derfler B: Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science 258:808, 1992
112. Winandy S, Wu P, Georgopoulos K: A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 83:289, 1995
113. Debatin KM, Goldman CK, Waldmann TA, Krammer PH: APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 81:2972, 1993
114. Debatin KM, Krammer PH: Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia 9:815, 1995
115. Lucking Famira KM, Daniel PT, Moller P, Krammer PH, Debatin KM: APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 8:1825, 1994
116. Cory S: Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13:513, 1995
117. Conroy LA, Alexander DR: The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Leukemia 10:1422, 1996
118. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
119. Kitada S, Krajewski S, Miyashita T, Krajewska M, Reed JC: Gamma-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene 12:187, 1996
120. Uckun FM, Yang Z, Sather HN, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zren T, Tubergen D, Reaman G, Gaynon P: Cellular expression of anti-apoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia. Blood 89:3769, 1997
121. Sen L, Borella L: Clinical importance of lymphoblasts with T markers in childhood acute leukemia. N Engl J Med 292:828, 1975
122. Borella L, Sen L: T-and B-lymphocytes and lymphoblasts in untreated acute lymphocytic leukemia. Cancer 34:646, 1974
123. Williams DL, Raimondi S, Rivera G, George S, Berard CW, Murphy SB: Presence of clonal chromosome abnormalities in virtually all cases of acute lymphoblastic leukemia [letter]. N Engl J Med 313:640, 1985
124. Pui CH, Crist WM, Look AT: Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449, 1990
125. Crist W, Boyett J, Pullen J, van Eys J, Vietti T: Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: A Pediatric Oncology Group review. Med Pediatr Oncol 14:135, 1986
126. Williams DL, Harber J, Murphy SB, Look AT, Kalwinsky DK, Rivera G, Melvin SL, Stass S, Dahl GV: Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia. Blood 68:205, 1986
127. Bloomfield CD, Goldman AJ, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, et al: Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 67:415, 1986
128. Look AT, Roberson PK, Williams DL, Rivera G, Bowman WP, Pui CH, Ochs J, Abromowitch M, Kalwinsky D, Dahl GV, et al: Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65:1079, 1985
129. Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, Borowitz M, Head D, Crist W: Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6: A Pediatric Oncology Group Study. Cancer 66:1183, 1990
130. Pui CH, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, et al: Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 76:590, 1990
131. Zintl F, Plenert W, Malke H: Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic. Hamatol Bluttransfus 30:471, 1987
132. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151, 1987
133. 9/L. J Clin Oncol 5:1015, 1987
134. Smith M, Arthur D, Camilla B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia [see comments]. J Clin Oncol 14:18, 1996
135. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard R, Jr., Coccia P, Leiken S, Lukens J, Neerhout R, Nesbit M, Miller DR, Reaman G, Sather H, Hammond D: Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 68:751, 1991
136. Henze G, Langermann HJ, Kaufmann U, Ludwig R, Schellong G, Stollmann B, Riehm H: Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 3:369, 1981
137. Pui CH, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174, 1990
138. Schaison G, Leverger G, Bancillon A, Marty M, Olive D, Cornu G, Griscelli C, Lemerle S, Harrousseau J, Bonnet M, Freycon F, Dufillot D, Demeocq F, Bauters F, Lamagnere J, Taboureau O: Intermediate risk childhood acute lymphoblastic leukemias: Anascrine + cytosine arabinoside versus intermediate dose methotrexate for consolidation, and 6 mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance. Hamatol Bluttransfus 30:461, 1987
139. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather HN, Hammond GD: Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. Am J Pediatr Hematol Oncol 10:42, 1988
140. Uckun F, Steinherz P, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G: CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: A Children's Cancer Group Study. Blood 88:4288, 1996
141. Uckun FM, Gaynon P, Sensel M, Nachman J, Trigg M, Steinherz P, Bostrom B, Sather H, Reaman G: Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group Study. J Clin Oncol 15:2214, 1997
142. Wiersma SR, Ortega J, Sobel E, Weinberg KJ: Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood [see comments]. N Engl J Med 324:800, 1991
143. Kurec AS, Belair P, Stefanu C, Barrett DM, Dubowy RL, Davey FR: Significance of aberrant immunophenotypes in childhood acute lymphoblastic leukemia. Cancer 67:3081, 1991
144. Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, Crist WM, Mirro J Jr: Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75:198, 1990
145. Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG: Unusual immunophenotypes in acute leukaemias: Incidence and clinical correlations. Br J Haematol 72:512, 1989
146. Uckun FM, Sather HN, Gaynon P, Arthur D, Trigg M, Tubergen D, Nachman J, Steinherz P, Sensel M, Reaman G: Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 90:28, 1997
147. Pieters R, Kaspers GJ, Klumper E, Veerman AJ: Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art. Med Pediatr Oncol 22:299, 1994
148. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ: Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19:407, 1995
149. Lauer SJ, Camitta BM, Leventhal BG, Mahoney DH Jr, Shuster JJ, Adair S, Casper JT, Civin CI, Graham M, Kiefer G, Pullen J, Steuber CP, Kamen B: Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 71:2854, 1993
150. Goker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI, Bertino JR: Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7:1000, 1993
151. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans WE: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564, 1994
152. Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ: Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group study. Cancer Res 45:6482, 1985
153. Costlow ME, Pui CH, Dahl GV: Glucocorticoid receptors in childhood acute lymphocytic leukemia. Cancer Res 42:4801, 1982
154. Gros P, Ben Neriah YB, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728, 1986
155. Laurent G, Frankel AE, Hertler AA, Schlossman DM, Casellas P, Jansen FK: Treatment of leukemia patients with T101 ricin a chain immunotoxins. Cancer Treat Res 37:483, 1988
156. Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJ, Pastan I: Cytotoxic activities of recombinant immunotoxins composed of pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 7:553, 1993
157. Waurzyniak B, Schneider E, Yanishevski Y, Gunther R, Chelstrom LM, Wendorf H, Myers DE, Irvin JD, Messinger Y, Ek O, Seren T, Langlie M, Evans WE, Uckun FM: In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunotoxin. Clin Cancer Res 3:881, 1997
158. Uckun FM, Reaman GH: Immunotoxins for treatment of leukemia and lymphoma.
159. Murphy JR, Bishai W, Borowski M, Miyanohara A, Boyd J, Nagle S: Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci USA 83:8258, 1986
160. Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I: Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Int J Cancer 57:856, 1994
161. LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T: Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 53:3930, 1993
162. Giblett ER: ADA and PNP deficiencies: How it all began. Ann NY Acad Sci 451:1, 1985
163. Kredich NM, Hershfield MS: Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency, in Stanbury JB, Wyngaarden JB, Goldstein JL, Brown MS (eds): The Metabolic Basis of Inherited Disease. New York, NY, McGraw-Hill, 1983, p 1157
164. Ullman B, Martin DW Jr: Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest 74:951, 1984
165. Verhoef V, Fridland A: Metabolic basis of arabinonucleoside selectivity for human leukemic T-and B-lymphoblasts. Cancer Res 45:3646, 1985
166. Hebert ME, Greenberg ML, Chaffee S, Gravatt L, Hershfield MS, Elion GB, Kurtzberg J: Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine. Transplantation 52:634, 1991
167. Gravatt LC, Chaffee S, Hebert ME, Halperin EC, Friedman HS, Kurtzberg J: Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: Application to an in vivo T-leukemia model. Leukemia 7:1261, 1993
168. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA: 2-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies. Cancer Res 55:3352, 1995
169. Plunkett W, Gandhi V, Nowak B, Du M, Rodriguez CO, Keating MJ: Pharmacokinetics of compound 506, a soluble prodrug of arabinosylguanine, in adult leukemias (meeting abstract). Proc Am Assoc Cancer Res 37:125, 1996